<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030420</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069164</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2304</secondary_id>
    <secondary_id>NCI-V01-1688</secondary_id>
    <nct_id>NCT00030420</nct_id>
  </id_info>
  <brief_title>Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs&#xD;
      used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining chemotherapy with celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and docetaxel in&#xD;
      treating patients who have advanced non-small cell lung cancer that has been previously&#xD;
      treated with platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy and feasibility of celecoxib combined with docetaxel in patients&#xD;
           with advanced non-small cell lung cancer previously treated with platinum-based&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Determine the response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral celecoxib twice daily (beginning on day -7 of the first course) and&#xD;
      docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2&#xD;
      additional courses after CR. Patients who achieve stable disease (SD) or a partial response&#xD;
      (PR) receive a minimum of 2 additional courses after SD or PR. At the discretion of the&#xD;
      treating physician, patients then receive maintenance therapy comprising celecoxib only.&#xD;
&#xD;
      Patients who discontinue therapy for disease progression or unacceptable toxicity are&#xD;
      followed for at least 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-39 patients will be accrued for this study within 13-28&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of combining Celecoxib with Docetaxel</measure>
    <time_frame>Weeks 1 , 2 and 3</time_frame>
    <description>Blood levels of VEGF &amp; PGE2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate of Celecoxib and Docetaxel</measure>
    <time_frame>Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation.</time_frame>
    <description>CT Chest/Abdomen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Celecoxib and Docetaxel</measure>
    <time_frame>Every week</time_frame>
    <description>Routine bloodwork</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of cyclooxygenase-2 (COX-2) in tumors</measure>
    <time_frame>Pre-study</time_frame>
    <description>Tissue sample from initial diagnosis, parrafin embedded tissue block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of prostaglandin E2 (PGE2) &amp; vascular endthelial growth factor (VEGF)</measure>
    <time_frame>Pre-study; Weeks 1 , 2 and 3</time_frame>
    <description>Collecting blood plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular changes induced in the tumor by celecoxib</measure>
    <time_frame>Weeks 1, 3 &amp; 6</time_frame>
    <description>Using DCE-MRI and PET scans to evaluate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib &amp; Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.&#xD;
Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.</description>
    <arm_group_label>Celecoxib &amp; Docetaxel</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>Celebra</other_name>
    <other_name>Onsenal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days</description>
    <arm_group_label>Celecoxib &amp; Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage IIIA, IIIB, or IV non-small cell lung cancer&#xD;
&#xD;
               -  Disease progression during or after 1 or more platinum-based chemotherapy&#xD;
                  regimens&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No symptomatic or untreated brain or leptomeningeal metastases&#xD;
&#xD;
               -  Previously treated patients must be neurologically stable for 4 weeks after&#xD;
                  completion of appropriate therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than ULN (or no greater than 2.5 times ULN if alkaline phosphatase&#xD;
             no greater than ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than ULN (or no greater than 5 times ULN if AST/ALT no&#xD;
             greater than ULN)&#xD;
&#xD;
          -  No history of chronic hepatitis of any duration&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction and/or stroke within the past 6 months&#xD;
&#xD;
          -  No active thromboembolic event within the past 4 weeks&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No gastrointestinal bleeding within the past 6 months&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior hypersensitivity reaction to docetaxel or other drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No prior allergy to any non-steroidal anti-inflammatory drug&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 3 years except adequately&#xD;
             treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious concurrent medical illness&#xD;
&#xD;
          -  No history of dementia, active psychiatric disorder, or other condition that would&#xD;
             interfere with ability to take oral medication or preclude compliance with study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Must weigh at least 50 kg (110 pounds)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  Prior paclitaxel allowed&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 days since prior steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to target lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs), including&#xD;
             rofecoxib or celecoxib, allowed&#xD;
&#xD;
          -  At least 1 week since prior fluconazole&#xD;
&#xD;
          -  No recent prior NSAIDs, including rofecoxib or celecoxib, for a duration of more than&#xD;
             30 consecutive days&#xD;
&#xD;
          -  No concurrent fluconazole or lithium&#xD;
&#xD;
          -  No other concurrent NSAIDs except aspirin administered at a dose of no more than 325&#xD;
             mg/day for cardiovascular conditions&#xD;
&#xD;
          -  No other concurrent cyclo-oxygenase-2 inhibitors&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirish M. Gadgeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schneider BJ, Kalemkerian GP, Kraut MJ, Wozniak AJ, Worden FP, Smith DW, Chen W, Gadgeel SM. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol. 2008 Dec;3(12):1454-9. doi: 10.1097/JTO.0b013e31818de1d2.</citation>
    <PMID>19057272</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>October 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2003</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

